{"id":40306,"date":"2021-04-01T07:44:47","date_gmt":"2021-04-01T07:44:47","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40306"},"modified":"2021-04-01T08:27:02","modified_gmt":"2021-04-01T08:27:02","slug":"croi-2021-monoclonal-antibodies-for-prevention-and-treatment-of-covid-19","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40306","title":{"rendered":"CROI 2021: New compounds for prevention and treatment of COVID-19"},"content":{"rendered":"<p><strong><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-40209\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo-213x300.png\" alt=\"\" width=\"213\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo-213x300.png 213w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2021\/03\/CROI-2021-logo.png 371w\" sizes=\"auto, (max-width: 213px) 100vw, 213px\" \/>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>CROI 2021 included important results from experimental treatments that reported positive results from early interventions, especially using monoclonal antibodies. Four short reports are included below.<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/i-base.info\/htb\/40358\">Molnupiravir significantly reduced SARS-CoV-2 viral load after five days in early infection<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/40360\">Bamlanivimab works as prophylaxis in high risk populations<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/40366\">Bamlanivimab and etesevimab (Eli-Lilly) reduced hospitalisation and mortality in mild\/moderate infection<\/a><\/li>\n<li><a href=\"https:\/\/i-base.info\/htb\/40368\">Casirivimab and imdevimab (Regeneron) dual mAbs reduce risk of symptomatic transmission<\/a><\/li>\n<\/ul>\n<p><em>This report was first published on 19 March 2021.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base CROI 2021 included important results from experimental treatments that reported positive results from early interventions, especially using monoclonal antibodies. Four short reports are included below. Molnupiravir significantly reduced SARS-CoV-2 viral load after five days in early &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,283,278],"tags":[307],"class_list":["post-40306","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19-investigational-drugs","category-covid-19","tag-croi-2021-virtual"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40306"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40306\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}